Literature DB >> 6121848

Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats.

H Araki, C Tanaka, H Fujiwara, M Nakamura, I Ohmura.   

Abstract

The pressor effect of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in rats and its decarboxylation in vivo have been examined. On i.v. administration, it produces a slow-onset and long-lasting pressor response, but no significant change in heart rate or e.c.g. The pressor effect was markedly reduced by inhibition of peripheral decarboxylase and by blockade of alpha-adrenoceptors. The slow-onset and long-acting pressor effect was also evident when the drug was given orally, while intracerebroventricular administration produced a long-lasting decrease in blood pressure. Noradrenaline (NA) concentrations in the plasma were significantly increased by both i.v. and oral administration of L-threo-DOPS. Elevation of plasma NA concentration by L-threo-DOPS given i.v. was suppressed by inhibition of decarboxylase. The plasma concentration of the drug was highest immediately after its i.v. administration. Its pressor effect was enhanced in rats made hypotensive by chemical sympathectomy with 6-hydroxydopamine (6-OHDA), compared with control rats, nevertheless, L-threo-DOPS produced the same increase in plasma NA concentrations in sympathectomized rats as in the controls. These results indicate that L-threo-DOPS is gradually converted to NA by L-aromatic amino acid decarboxylase in vivo. These findings suggest that L-threo-DOPS may be clinically useful as an oral pressor agent for the treatment of certain disorders related to hypotension.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6121848     DOI: 10.1111/j.2042-7158.1981.tb13929.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Increase in the blood pressure and decrease in the norepinephrine release in the ventrolateral medulla during intraventricular administration of hypertonic NaCl.

Authors:  K Katahira; H Mikami; T Tsunetoshi; K Kohara; A Otsuka; M Nagano; T Ogihara
Journal:  Pflugers Arch       Date:  1989-09       Impact factor: 3.657

2.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

3.  Shy-Drager syndrome. Effect of fludrocortisone and L-threo-3,4-dihydroxyphenylserine on the blood pressure and regional cerebral blood flow.

Authors:  S Matsubara; Y Sawa; H Yokoji; M Takamori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

4.  Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.

Authors:  T Suzuki; S Higa; S Sakoda; M Ueji; A Hayashi; Y Takaba; A Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  The noradrenaline precursor L-threo-3,4-dihydroxyphenylserine exhibits antinociceptive activity via central alpha-adrenoceptors in the mouse.

Authors:  A Kawabata; K Kasamatsu; N Umeda; H Takagi
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

6.  DL-threo-DOPS as a precursor of noradrenaline.

Authors:  A Reches; V Jackson-Lewis; S Fahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.